CNTA Stock Summary and Trading Ideas (Centessa Pharmaceuticals PLC - American Depositary Shares | NASDAQ:CNTA)

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.

Centessa Pharmaceuticals PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol CNTA.

As of March 17, 2026, CNTA stock price climbed to $28.95 with 973,101 million shares trading.

CNTA has a beta of 1.29, meaning it tends to be more sensitive to market movements. CNTA has a correlation of 0.12 to the broad based SPY ETF.

CNTA has a market cap of $4.28 billion. This is considered a Mid Cap stock.

Last quarter Centessa Pharmaceuticals PLC - American Depositary Shares reported $0 in Revenue and -$.41 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.02.

In the last 3 years, CNTA traded as high as $30.58 and as low as $3.38.

The top ETF exchange traded funds that CNTA belongs to (by Net Assets): IBB, CGMM, TMSL, FFSM, ONEQ.

CNTA has outperformed the market in the last year with a price return of +68.9% while the SPY ETF gained +20.5%. CNTA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +12.6% and +9.2%, respectively, while the SPY returned -0.9% and -2.3%, respectively.

CNTA support price is $27.32 and resistance is $29.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CNTA shares will trade within this expected range on the day.